Despite the small sample size in the molecular subgroups, the limited number of patients in the AZA group and the lack of thorough analysis between the IDH-mutant isoforms and concomitant mutations, the combination of VEN-AZA emerged as a very good competitive candidate for the IDH-mutated AML, apart from treatment option with the IDH inhibitors [enasidenib, ivosidenib (IVO), olutasidenib] (17, 18). Here, IDH2 is linked to acute myeloid leukemia.